Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CD133 bispecific CAR-T
- Development stage
- Preclinical
- Lead developer
- Imperial College London
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-CD133 bispecific CAR-T is a preclinical chimeric antigen receptor T-cell (CAR-T) therapy that simultaneously targets two antigens: CD19, a pan-B-cell surface antigen, and CD133 (also known as PROM1), a stem cell marker that is directly regulated by KMT2A-fusion oncoproteins. This dual-targeting approach is designed to enhance antileukemic activity and reduce the risk of immune escape in high-risk KMT2A-rearranged (KMT2Ar) acute leukemias, which typically express both markers. Research presented at ASH 2025 indicates that while this construct is effective, CAR-iNKT cells using the same bispecific CAR may offer superior trafficking and retention in the leptomeningeal space compared to standard CAR-T cells due to enhanced VLA-4-mediated adhesion.
- Other names
- CD19/CD133 bispecific CAR-TCD19/CD133 CAR-T
02
Targets
CD133 (CD133 antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on CD19-CD133 bispecific CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CD133 bispecific CAR-T.